Jiangsu Bioperfectus Technologies Co., Ltd.

Jiangsu Bioperfectus Technologies Co., Ltd. specializes in developing in vitro diagnostic (IVD) kits for detecting SARS-CoV-2, the virus responsible for COVID-19. Their products use nucleic acid testing (NAT), specifically real-time PCR technology, to identify viral RNA from patient samples. These kits are designed for laboratory use to assist in diagnosing COVID-19 infections.

Jiangsu Bioperfectus Technologies Co., Ltd. is based in the United States, which means its devices are subject to FDA regulatory requirements. The company’s SARS-CoV-2 diagnostic kits fall under FDA’s Class II device classification, indicating a moderate level of regulatory scrutiny due to their role in detecting infectious diseases. This classification helps ensure their performance, safety, and effectiveness are rigorously evaluated.

Yes, Jiangsu Bioperfectus Technologies Co., Ltd.’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This listing is important because it provides transparency on the device’s identity, regulatory status, and compliance with FDA requirements. The UDI system helps healthcare providers, laboratories, and regulators track and verify the device’s authorization, ensuring proper use and reducing risks associated with counterfeit or unapproved products.

Jiangsu Bioperfectus Technologies Co., Ltd.’s SARS-CoV-2 diagnostic kits are classified as Class II devices by the FDA. This classification is based on the device’s intended use—detecting infectious diseases—and the associated risks. Class II devices require special controls beyond general controls (like good manufacturing practices) to ensure safety and effectiveness. While they don’t pose the highest risk (like Class III devices), they still undergo rigorous review to validate their performance in identifying viral infections accurately.